Tags

Type your tag names separated by a space and hit enter

Effect of add-on gabapentin on opioid withdrawal symptoms in opium-dependent patients.
Addiction. 2008 Sep; 103(9):1495-9.A

Abstract

AIMS

Evaluation of the efficacy of gabapentin in patients undergoing out-patient treatment for opiate withdrawal.

DESIGN

A 3-week double-blind, randomized, placebo-controlled trial of adjunctive gabapentin in methadone-assisted detoxification (MAD).

SETTING

Specialized Addictive Behaviors Unit, an out-patient unit for the treatment of patients with an addictive disorder serving the city of Isfahan (Iran).

PARTICIPANTS

Forty out-patients, 37 males and three females, aged 21-61 years, who met DSM-IV criteria for opiate dependence.

INTERVENTION

Random assignment of subjects to receive adjunctive treatment with either gabapentin (900 mg/day) or placebo under double-blind conditions.

MEASUREMENTS

Severity of subjective withdrawal symptoms using the Subjective Opiate Withdrawal Scale at six stages.

FINDINGS

Despite the superiority of gabapentin on controlling some of withdrawal symptoms, no significant differences were reported between two groups.

CONCLUSIONS

Dosage of 900 mg/day of gabapentin is not significantly superior to placebo in controlling opiate withdrawal symptoms.

Authors+Show Affiliations

Behavioral Sciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. kheirabadi@bsrc.mul.ac.irNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18783503

Citation

Kheirabadi, Gholam R., et al. "Effect of Add-on Gabapentin On Opioid Withdrawal Symptoms in Opium-dependent Patients." Addiction (Abingdon, England), vol. 103, no. 9, 2008, pp. 1495-9.
Kheirabadi GR, Ranjkesh M, Maracy MR, et al. Effect of add-on gabapentin on opioid withdrawal symptoms in opium-dependent patients. Addiction. 2008;103(9):1495-9.
Kheirabadi, G. R., Ranjkesh, M., Maracy, M. R., & Salehi, M. (2008). Effect of add-on gabapentin on opioid withdrawal symptoms in opium-dependent patients. Addiction (Abingdon, England), 103(9), 1495-9. https://doi.org/10.1111/j.1360-0443.2008.02248.x
Kheirabadi GR, et al. Effect of Add-on Gabapentin On Opioid Withdrawal Symptoms in Opium-dependent Patients. Addiction. 2008;103(9):1495-9. PubMed PMID: 18783503.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of add-on gabapentin on opioid withdrawal symptoms in opium-dependent patients. AU - Kheirabadi,Gholam R, AU - Ranjkesh,Mansour, AU - Maracy,Mohamad R, AU - Salehi,Mehrdad, PY - 2008/9/12/pubmed PY - 2008/12/24/medline PY - 2008/9/12/entrez SP - 1495 EP - 9 JF - Addiction (Abingdon, England) JO - Addiction VL - 103 IS - 9 N2 - AIMS: Evaluation of the efficacy of gabapentin in patients undergoing out-patient treatment for opiate withdrawal. DESIGN: A 3-week double-blind, randomized, placebo-controlled trial of adjunctive gabapentin in methadone-assisted detoxification (MAD). SETTING: Specialized Addictive Behaviors Unit, an out-patient unit for the treatment of patients with an addictive disorder serving the city of Isfahan (Iran). PARTICIPANTS: Forty out-patients, 37 males and three females, aged 21-61 years, who met DSM-IV criteria for opiate dependence. INTERVENTION: Random assignment of subjects to receive adjunctive treatment with either gabapentin (900 mg/day) or placebo under double-blind conditions. MEASUREMENTS: Severity of subjective withdrawal symptoms using the Subjective Opiate Withdrawal Scale at six stages. FINDINGS: Despite the superiority of gabapentin on controlling some of withdrawal symptoms, no significant differences were reported between two groups. CONCLUSIONS: Dosage of 900 mg/day of gabapentin is not significantly superior to placebo in controlling opiate withdrawal symptoms. SN - 0965-2140 UR - https://www.unboundmedicine.com/medline/citation/18783503/Effect_of_add_on_gabapentin_on_opioid_withdrawal_symptoms_in_opium_dependent_patients_ L2 - https://doi.org/10.1111/j.1360-0443.2008.02248.x DB - PRIME DP - Unbound Medicine ER -